Management of Bleeding with Newer Anticoagulants

Authors

  • Athanasios Pipilis “Hygeia” Hospital, Athens, Greece

DOI:

https://doi.org/10.2015/hc.v9i1%20Sup.630

Keywords:

dabigatran, rivaroxaban, apixaban, bleeding

Abstract

Several novel oral anticoagulant drugs (NOACs) have recently been approved for use in patients with non-valvular atrial fibrillation or venous thromboembolic disease. These drugs are either direct thrombin inhibitors (dabigatran) or factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and all have been compared in large randomized trials with warfarin. In general, NOACs are considered, at least, non-inferior to warfarin in terms of stroke prevention but their risk of bleeding is variable.

Downloads

Published

2014-05-15

Issue

Vol. 9 No. 1 Sup (2014): ATHENS CARDIOLOGY UPDATE 2014

Section

ATHENS CARDIOLOGY UPDATE 2014

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).